Skip to Content

Companies Developing Vaccines Against New Coronavirus Variants

THURSDAY, Feb. 4, 2021 -- As concerns mount about mutations that could make the new coronavirus more difficult to fight, two companies say they are working to develop new vaccines against emerging variants of the virus that causes COVID-19.

GlaxoSmithKline is teaming with German biopharmaceutical company CureVac to create vaccines that use messenger RNA to combat the coronavirus, the Associated Press reported.

"The increase in emerging variants with the potential to reduce the efficacy of first generation COVID-19 vaccines requires acceleration of efforts to develop vaccines against new variants to keep one step ahead of the pandemic," according to a statement from the companies.

Their announcement comes as public health officials worldwide express worry about new coronavirus variants from Britain, South Africa, and Brazil that are more contagious or resistant to current vaccines, the AP reported. Mutations in the virus are being closely monitored by scientists in an attempt to quickly identify potentially dangerous variants.

"We believe that next generation vaccines will be crucial in the continued fight against COVID-19," GSK Chief Executive Emma Walmsley said in the statement, the AP reported.

Associated Press Article

© 2021 HealthDay. All rights reserved.

Posted: February 2021

Read this next

Racial/Ethnic Minorities Underrepresented in Vaccine Trials

THURSDAY, Feb. 25, 2021 -- There is underrepresentation of racial/ethnic minorities and older patients among U.S.-based vaccine clinical trials, while female adults are...

Risk Reduced for Positive NAAT Result With SARS-CoV-2 Antibodies

THURSDAY, Feb. 25, 2021 -- Having severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies is associated with a reduced risk for future infection, according to a...

FDA Review Reveals J&J COVID-19 Vaccine Safe, Effective

WEDNESDAY, Feb. 24, 2021 -- A single-shot COVID-19 vaccine made by Johnson & Johnson completely prevented hospitalizations and deaths in a large clinical trial, according to...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.